TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29239764

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 9585

Group type: EXPERIMENTAL
Intervention: Sulphonylureas
Number of subjects: 9585

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 9585

Group type: EXPERIMENTAL
Intervention: Dipeptidyl peptidase 4 inhibitors (DPP‐4i)
Number of subjects: 9585

Group type: EXPERIMENTAL
Intervention: Sitagliptin and Saxagliptin
Number of subjects: 9585
Study: 26894800

Group type: EXPERIMENTAL
Intervention: IDegLira
Number of subjects: 0
Study: 25341118

Group type: EXPERIMENTAL
Intervention: Vedolizumab (VDZ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24294977

Group type: EXPERIMENTAL
Intervention: New Nordic Diet (NND)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Average Danish Diet (ADD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjusted Average Danish Diet (ADD-m)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjusted New Nordic Diet (NND-m)
Number of subjects: 0
Study: 20022733

Group type: EXPERIMENTAL
Intervention: DHA supplementation during pregnancy and lactation
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Erythrocyte DHA levels
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Erythrocyte Arachidonic Acid (AA) levels
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: DHA/AA ratio
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Mead acid levels
Number of subjects: 57
Study: 18004688

Group type: EXPERIMENTAL
Intervention: High GI and high GL (HH)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Low GI and low GL (LL)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High GI and low GL (HL)
Number of subjects: 9
Study: 16893753

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Papaverine
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 85

Group type: COMPARATOR
Intervention: Normal Saline (Control)
Number of subjects: 85
Study: 14644697

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention group receiving a 5-year behavioral dietary and physical activity program
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention group
Number of subjects: 535
Study: 10706432

Group type: EXPERIMENTAL
Intervention: True information about performance (Condition A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: False information about performance (Condition B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Learning effect observed in both conditions
Number of subjects: 0
Study: 9037359

Group type: EXPERIMENTAL
Intervention: PEB (cisplatin, etoposide, bleomycin)
Number of subjects: 54

Group type: COMPARATOR
Intervention: CEB (carboplatin, etoposide, bleomycin)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Negative events
Number of subjects: 54
Study: 1909748

Group type: EXPERIMENTAL
Intervention: Transdermal nitrate therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral nitrate therapy
Number of subjects: 0
Study: 6397454

Group type: EXPERIMENTAL
Intervention: Indomethacin together with low dose dopamine infusion
Number of subjects: 15

Group type: COMPARATOR
Intervention: Indomethacin alone
Number of subjects: 15
Study: 31619300

Group type: EXPERIMENTAL
Intervention: Surgical site infections (SSIs)
Number of subjects: 4556

Group type: COMPARATOR
Intervention: Non-surgical site infections (non-SSIs)
Number of subjects: 4556

Group type: EXPERIMENTAL
Intervention: Private insurance
Number of subjects: 4556

Group type: EXPERIMENTAL
Intervention: ICU admission
Number of subjects: 4556

Group type: COMPARATOR
Intervention: NHS England simulation
Number of subjects: 4556
Study: 29560795

Group type: EXPERIMENTAL
Intervention: Nurse assessment of PICC site using a seven-item assessment tool
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Patient assessment of PICC site using a seven-item assessment tool
Number of subjects: 73
Study: 26753792

Group type: EXPERIMENTAL
Intervention: Methadone treatment
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Younger patients
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Patients with pain
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Patients with high or very high nicotine dependence
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Patients at suicidal risk
Number of subjects: 173
Study: 24524214

Group type: EXPERIMENTAL
Intervention: 9-week online insomnia treatment programme, Sleep Healthy Using The internet (SHUTi)
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Online attention-matched control group (HealthWatch)
Number of subjects: 1600
Study: 23018304

Group type: EXPERIMENTAL
Intervention: 1.6% hyaluronic acid/4.0% chondroitin sulfate
Number of subjects: 39

Group type: COMPARATOR
Intervention: 2.0% hydroxypropylmethylcellulose
Number of subjects: 39
Study: 20231896

Group type: EXPERIMENTAL
Intervention: Intravenous sodium stibogluconate (SSG) 20mg/kg/day for ten doses
Number of subjects: 56

Group type: COMPARATOR
Intervention: Localized ThermoMed (TM) device heat treatment (applied at 50 degrees C for 30 seconds) in one session
Number of subjects: 56
Study: 17398320

Group type: EXPERIMENTAL
Intervention: 5 IU/ml low-molecular-weight heparin (LMWH) and 200 mug/ml 5-Fluorouracil (5FU) added to the perioperative infusion fluid
Number of subjects: 641

Group type: COMPARATOR
Intervention: Placebo (no adjuvant therapy)
Number of subjects: 641
Study: 15542577

Group type: EXPERIMENTAL
Intervention: Bicycle exercise (50% of peak oxygen uptake)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (seated rest)
Number of subjects: 21
Study: 12188401

Group type: EXPERIMENTAL
Intervention: Simvastatin (Zocor), dosage 10 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Generic simvastatin (Unison), dosage 10 mg
Number of subjects: 48
Study: 11938791

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 80

Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Misoprostol (rectum or vagina)
Number of subjects: 80
Study: 8887188

Group type: EXPERIMENTAL
Intervention: Oral contraceptive (OC) therapy after GnRH-a administration
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Combination therapy (GnRH-a plus OC 'addback') for six months
Number of subjects: 23

Group type: COMPARATOR
Intervention: GnRH-a (depot every 28 days) for six months
Number of subjects: 23
Study: 1324109

Group type: EXPERIMENTAL
Intervention: Positive verbalizations (VP)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Negative verbalizations (VN)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (T)
Number of subjects: 46
Study: 6326562

Group type: EXPERIMENTAL
Intervention: Guar gum (15 g/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30647402

Group type: EXPERIMENTAL
Intervention: Intercostal nerve block with ropivacaine (group A)
Number of subjects: 100
Study: 30302335

Group type: EXPERIMENTAL
Intervention: Once daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 µg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Twice daily budesonide/formoterol (BUD/FOR) 400/12 μg
Number of subjects: 0
Study: 27717374

Group type: EXPERIMENTAL
Intervention: Minding the Baby® (MTB) programme
Number of subjects: 200

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 200
Study: 24962856

Group type: EXPERIMENTAL
Intervention: ART (Augmented Reality Telementoring)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Traditional mentoring
Number of subjects: 19
Study: 21159473

Group type: EXPERIMENTAL
Intervention: Midazolam 1.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diphenhydramine 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20137360

Group type: EXPERIMENTAL
Intervention: Morphine (0.15 mg/kg; maximum 20 mg)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 106
Study: 18721708

Group type: EXPERIMENTAL
Intervention: AcrySof SN60AT IOL
Number of subjects: 36

Group type: COMPARATOR
Intervention: AF‐1 YA‐60BB IOL
Number of subjects: 36
Study: 16512103

Group type: EXPERIMENTAL
Intervention: Yogurt containing Bifidobacterium DN-173 010 (200 g once daily for 2 weeks)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control yogurt without viable bacteria (200 g once daily for 2 weeks)
Number of subjects: 21
Study: 12466782

Group type: EXPERIMENTAL
Intervention: Acipimox (250 mg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Hyperinsulinemic euglycemic clamping
Number of subjects: 90

Group type: COMPARATOR
Intervention: Comparison of image quality
Number of subjects: 90
Study: 9951429

Group type: EXPERIMENTAL
Intervention: R-568 (calcium receptor agonist)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: R-568 (80 to 160 mg doses)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: R-568
Number of subjects: 18
Study: 7844610

Group type: EXPERIMENTAL
Intervention: Diethyldithiocarbamate (DDTC) 1.6 g/m2 over 4 hours, administered intravenously every 4 weeks for six cycles
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo (PB), administered intravenously every 4 weeks for six cycles
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Diethyldithiocarbamate (DDTC)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo (PB)
Number of subjects: 221
Study: 2189954

Group type: EXPERIMENTAL
Intervention: MVAC chemotherapy
Number of subjects: 110

Group type: COMPARATOR
Intervention: CISCA chemotherapy
Number of subjects: 110
Study: 446321

Group type: EXPERIMENTAL
Intervention: Additional treatment with piracetam (Normabrain, Nootrop, 9 g/d intravenously)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 36
Study: 30535355

Group type: EXPERIMENTAL
Intervention: Oxytocin (OXT)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 187
Study: 30773864

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Acupoint catgut embedding
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both interventions (EA and catgut embedding)
Number of subjects: 84
Study: 29117276

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 27564

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27564
Study: 26031193

Group type: EXPERIMENTAL
Intervention: 5-HTP (100 mg orally)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 23609398

Group type: EXPERIMENTAL
Intervention: haloperidol (2.5 mg) + midazolam (7.5 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: olanzapine (10 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: haloperidol (2.5 mg) + promethazine (25 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ziprasidone (10 mg)
Number of subjects: 100
Study: 21893650

Group type: EXPERIMENTAL
Intervention: Cycled therapy (tobramycin inhalation solution 300 mg twice a day for 28 days + oral ciprofloxacin 15-20 mg/kg twice a day for 14 days every quarter)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Culture-based therapy (same treatments only during quarters with positive P aeruginosa cultures)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (15-20 mg/kg twice a day for 14 days every quarter)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo (oral placebo for 14 days every quarter)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Cycled therapy
Number of subjects: 304

Group type: COMPARATOR
Intervention: Culture-based therapy
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study: 19837207

Group type: EXPERIMENTAL
Intervention: Group psychotherapy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 16750681

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 140
Study: 15363569

Group type: EXPERIMENTAL
Intervention: 25 mg clomipramine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 20 mg paroxetine
Number of subjects: 30

Group type: COMPARATOR
Intervention: paroxetine
Number of subjects: 30

Group type: COMPARATOR
Intervention: clomipramine
Number of subjects: 30
Study: 11731062

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTXA) injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline injection (control)
Number of subjects: 0
Study: 9230003

Group type: EXPERIMENTAL
Intervention: Intravenous amphotericin B lipid complex at 5 mg/kg total dose (1 mg/kg per day for 5 days)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous amphotericin B lipid complex at 10 mg/kg total dose (2 mg/kg per day for 5 days)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous amphotericin B lipid complex at 15 mg/kg total dose (3 mg/kg per day for 5 days)
Number of subjects: 60
Study: 8040900

Group type: EXPERIMENTAL
Intervention: nHuIFN-alpha
Number of subjects: 188

Group type: COMPARATOR
Intervention: AZT
Number of subjects: 188

Group type: COMPARATOR
Intervention: Nothing (untreated controls)
Number of subjects: 188
Study: 2902812

Group type: EXPERIMENTAL
Intervention: 5 mg kg‐1 cimetidine (groups 3 and 5)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.2‐0.3 mg kg‐1 etomidate (groups 2 and 3)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2‐3 mg kg‐1 thiopentone (groups 1, 4, 5 and 6)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.08 mg kg‐1 vecuronium
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1.25 mg kg‐1 ranitidine (group 6)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.002 mg kg‐1 fentanyl and 0.01 mg kg‐1 lormetazepam
Number of subjects: 60
Study: 1218149

Group type: EXPERIMENTAL
Intervention: Althesin (alphaxalone and alphadolone acetate)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Pancuronium bromide
Number of subjects: 32
Study: 31461123

Group type: EXPERIMENTAL
Intervention: Multifaceted mobile technology-supported intervention
Number of subjects: 6579

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 6579
Study: 28396303

Group type: EXPERIMENTAL
Intervention: SoSu‐life tool
Number of subjects: 566

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 566
Study: 26134386

Group type: EXPERIMENTAL
Intervention: Ultra-short stem
Number of subjects: 51

Group type: COMPARATOR
Intervention: Conventional tapered stem
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 51
Study: 24206640

Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg twice daily
Number of subjects: 288

Group type: COMPARATOR
Intervention: Sorafenib 400 mg twice daily
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Axitinib
Number of subjects: 288

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 288
Study: 21884529

Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM) 500 mg for 3 days during the first week, followed by 500 mg per week for the next 11 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM)
Number of subjects: 60
Study: 19726140

Group type: EXPERIMENTAL
Intervention: Two brief Motivational Interviewing (MI) sessions
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 126
Study: 17898353

Group type: EXPERIMENTAL
Intervention: Amisulpride (dopamine D(2)/D(3) antagonist)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 15485015

Group type: EXPERIMENTAL
Intervention: 186Re-sulfide (64 +/- 4 MBq)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Cortivazol (Altim) 3.75 mg
Number of subjects: 81
Study: 11152924

Group type: EXPERIMENTAL
Intervention: Vaginal preparation with povidone iodine
Number of subjects: 498

Group type: COMPARATOR
Intervention: No preparation (control)
Number of subjects: 498
Study: 9766255

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rh-GH) 0.5-1 IU/day s.c., bedtime (n=8)
Number of subjects: 29

Group type: COMPARATOR
Intervention: placebo (n=7)
Number of subjects: 29

Group type: COMPARATOR
Intervention: rh-GH vs placebo
Number of subjects: 29
Study: 9138880

Group type: EXPERIMENTAL
Intervention: Large Lin's biopsy forceps
Number of subjects: 81

Group type: COMPARATOR
Intervention: Small conventional biopsy forceps
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Large Lin's grasping forceps
Number of subjects: 81
Study: 3041874

Group type: EXPERIMENTAL
Intervention: Plasmapheresis (10 ml plasma/kgbw) using a Haemonetics separator (PCS) after premedication before anaesthesia.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no plasma withdrawal) measured at identical times as the plasmapheresis group.
Number of subjects: 30
Study: 29280500

Group type: EXPERIMENTAL
Intervention: PANSS-8
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: PANSS-6
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: PANSS-30
Number of subjects: 270
Study: 26350489

Group type: EXPERIMENTAL
Intervention: Autologous adipose-derived stromal vascular fraction (ADSVF) injection
Number of subjects: 12
Study: 24286192

Group type: EXPERIMENTAL
Intervention: LNG-IUS (Levonorgestrel-impregnated intrauterine device)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Continuous oral MPA (10 mg daily for 6 months)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Cyclic oral MPA (10 mg for 10 days per cycle for 6 months)
Number of subjects: 170
Study: 24330904

Group type: EXPERIMENTAL
Intervention: EPA/DHA supplementation (n = 1,046)
Number of subjects: 2081

Group type: EXPERIMENTAL
Intervention: EPA/DHA supplementation as monotherapy (n = 125)
Number of subjects: 2081

Group type: EXPERIMENTAL
Intervention: EPA/DHA supplementation as adjunctive to conventional antidepressants (n = 33)
Number of subjects: 2081

Group type: COMPARATOR
Intervention: Placebo (n = 1,035)
Number of subjects: 2081
Study: 20957321

Group type: EXPERIMENTAL
Intervention: Dydrogesterone (5 mg)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Calcium plus Vitamin D (500 mg calcium + 200 mg vitamin D)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 18375891

Group type: EXPERIMENTAL
Intervention: darbepoetin/iron (sodium ferric gluconate 125 mg IV weekly for the first 6 weeks)
Number of subjects: 149

Group type: COMPARATOR
Intervention: darbepoetin (no iron)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: darbepoetin/iron
Number of subjects: 149
Study: 16753767

Group type: EXPERIMENTAL
Intervention: L-arginine (20 g/500 mL) administered via i.v. infusion for 4 consecutive days
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: L-arginine (in subgroup not receiving antihypertensive drugs)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (in subgroup not receiving antihypertensive drugs)
Number of subjects: 43
Study: 12820059

Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted distal gastrectomy (LADG)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Open distal gastrectomy (ODG)
Number of subjects: 20
Study: 10711609

Group type: EXPERIMENTAL
Intervention: Flap with tension
Number of subjects: 11

Group type: COMPARATOR
Intervention: Flap without tension
Number of subjects: 11
Study: 9554154

Group type: EXPERIMENTAL
Intervention: Western blot method for detecting antibodies against rotavirus proteins
Number of subjects: 45
Study: 7699621

Group type: EXPERIMENTAL
Intervention: Low-dose methotrexate (MTX) therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control sera
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MTX nonresponders
Number of subjects: 0
Study: 2958727

Group type: EXPERIMENTAL
Intervention: Maylard incision
Number of subjects: 97

Group type: COMPARATOR
Intervention: Pfannenstiel incision
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Both Maylard and Pfannenstiel incisions
Number of subjects: 97
Study: 29074041

Group type: EXPERIMENTAL
Intervention: Bilateral sphenopalatine ganglion block with lidocaine 2%
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sham operation with water for injection
Number of subjects: 33
Study: 27493136

Group type: EXPERIMENTAL
Intervention: Empagliflozin 12.5 mg b.i.d. + Metformin 1,000 mg b.i.d.
Number of subjects: 1364

Group type: EXPERIMENTAL
Intervention: Empagliflozin 12.5 mg b.i.d. + Metformin 500 mg b.i.d.
Number of subjects: 1364

Group type: EXPERIMENTAL
Intervention: Empagliflozin 5 mg b.i.d. + Metformin 1,000 mg b.i.d.
Number of subjects: 1364

Group type: EXPERIMENTAL
Intervention: Empagliflozin 5 mg b.i.d. + Metformin 500 mg b.i.d.
Number of subjects: 1364

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg q.d.
Number of subjects: 1364

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg q.d.
Number of subjects: 1364

Group type: COMPARATOR
Intervention: Metformin 1,000 mg b.i.d.
Number of subjects: 1364

Group type: COMPARATOR
Intervention: Metformin 500 mg b.i.d.
Number of subjects: 1364
Study: 26719017

Group type: EXPERIMENTAL
Intervention: Intraductal stent group (IST) - custom-made segment of a T-tube placed into the bile duct, removed endoscopically 4 to 6 months later.
Number of subjects: 248

Group type: COMPARATOR
Intervention: Control group - biliary reconstruction without an intraductal stent.
Number of subjects: 248
Study: 23761968

Group type: EXPERIMENTAL
Intervention: RSDM+ (monthly risedronate 150 mg and cholecalciferol 30,000 IU combined in a single pill, n = 74)
Number of subjects: 150

Group type: COMPARATOR
Intervention: RSDM (monthly risedronate 150 mg alone, n = 76)
Number of subjects: 150
Study: 21401729

Group type: EXPERIMENTAL
Intervention: Tacrolimus/Mycophenolate Mofetil (Tacr/MMF)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Tacrolimus/Azathioprine (Tacr/Aza)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 77
Study: 18544983

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (total doses of 60 Gy with single doses of 2 Gy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy for pT3 tumors with positive margins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy for pT2 R1 tumors
Number of subjects: 0